 | |
| Company type | Public (Nasdaq: SLN) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1994 |
| Headquarters | Hammersmith, London |
Number of employees | 120 |
| Website | www.silence-therapeutics.com |
Silence Therapeutics (Nasdaq: SLN[1]), is a London-based pharmaceutical company formed in 1994. The company since its inception has pioneered the design and development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.[2]
Profile[edit]
Silence Therapeutics develops medicines related to RNA interference or RNAi,[3] to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD™ platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver. Silence Therapeutic's product candidates include SLN124, designed to address rare hematological diseases, and zerlasiran (formerly SLN360), designed to address the unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a), a key genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after. [4]
Partnerships[edit]
Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.[5]
References[edit]
- ^ "Google Finance Stock Exchange listing for Silence Therapeutics".
- ^ "About us". silence-therapeutics.com. Archived from the original on 26 March 2023. Retrieved 26 June 2023.
- ^ Hannon, Gregory J. (July 2002). "RNA interference". Nature. pp. 244–251. doi:10.1038/418244a. Retrieved 26 June 2023.
- ^ Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
- ^ "Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023|
